Introduced by Mr. Scott Cooke, Prof. Pierre Coulie, kicked of the meeting by providing an overview of the learnings gained with immunotherapy in recent decades, as well as an indication of future directions in coming years.
Prof. Ahmad Awada provides an overview of the lessons on checkpoint inhibitors that have been learned to date and new perspectives in immuno-oncology, in a plenary session chaired by Prof. Patrick Pauwels.
Prof. Karim Vermaelen gives a presentation on the current status of the immuno-oncology biomarker landscape, in a plenary session chaired by Prof. Patrick Pauwels.
In this interactive workshop, moderated by Prof. Bernard Lauwerys, Prof. Eric Van Cutsem and Dr Olivier Malaise address four key questions on the management of patients with underlying autoimmune diseases who are being treated with checkpoint inhibitors.
Dr Sandrine Aspeslagh gives an overview of immune-related adverse events (irAEs) and provides practical recommendations for the management of common and rare irAEs in two workshops moderated by Dr Stefan Rauh and Prof. Guy Jerusalem, respectively.
Common adverse events
Rare adverse events
Together with moderator Prof. Karim Vermaelen, Prof. Sylvie Rottey provides practice-informing guidance on immmunotherapy treatment of patients with pre-existing and/or concomitant medications.
In this workshop, moderated by Prof. Pierre Coulie, Prof. Jean-Pascal Machiels explains the rationale of combining immuno-oncology agents with other cancer therapies.
Prof. Johan Vansteenkiste provides an overview of the measurement of tumor response in this new immuno-oncology era. Dr Stefan Rauh completes this interactive workshop with some patient cases.
These sessions, chaired by Prof. Rik Schots focus on the importance of immunotherapy and management of adverse events in two therapeutic areas: Prof. Tessa Kerre discusses CAR-T therapy in hematology, while Prof. Eric Van Cutsem gives an overview of immunotherapy in digestive oncology.
Prof Kerre - Hematology
Prof Van Cutsem-GI cancers